Title | Creator | Date | ||
---|---|---|---|---|
1 | Should Immunosuppressive Therapy Be Modified During a Pandemic? | Marc A. Bouffard; Michael Levy; Andrew G. Lee; Gregory P. Van Stavern | 2021-06 | |
2 | Delayed Diagnosis of Posterior Reversible Encephalopathy Syndrome: A Case Report | Roma Pegany; Daniel J. Olson; Khalid M. Aldaas; Kevin R. Sitko | 2021-03 | |
3 | The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis | Jodie M. Burton, MD, MSc, FRCPC; Mark S. Freedman, MSc, MD, FAAN, FANA, FRCPC | 2018-06 | |
4 | Tacrolimus Optic Neuropathy | Nailyn Rasool, MD, FRCPC; Katherine Boudreault, MD, FRCSC; Simmons Lessell, MD; Sashank Prasad, MD; Dean M. Cestari, MD | 2018-06 | |
5 | Extraocular Muscle Findings in Myasthenia Gravis Associated Treatment-Resistant Ophthalmoplegia | Robyn M. Rautenbach, MSc; Komala Pillay, MBChB; Anthony D. N. Murray, MBChB; Jeannine M. Heckmann, PhD | 2017-12 | |
6 | How Neurologists and Neuro-Ophthalmologists Think | Michael Benatar, MD, PhD | 2016-03 | |
7 | Does Treatment of Ocular Myasthenia Gravis With Early Immunosuppressive Therapy Prevent Secondarily Generalization and Should It Be Offered to All Such Patients? | Sui H. Wong, MRCP; Gordon T. Plant, FRCP, FRCOphth; Wayne Cornblath, MD | 2016-03 |